JP2009525478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525478A5 JP2009525478A5 JP2008552858A JP2008552858A JP2009525478A5 JP 2009525478 A5 JP2009525478 A5 JP 2009525478A5 JP 2008552858 A JP2008552858 A JP 2008552858A JP 2008552858 A JP2008552858 A JP 2008552858A JP 2009525478 A5 JP2009525478 A5 JP 2009525478A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- prongf
- body fluid
- biological sample
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 9
- 239000012472 biological sample Substances 0.000 claims 7
- 210000001124 body fluid Anatomy 0.000 claims 7
- 239000010839 body fluid Substances 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 201000002510 thyroid cancer Diseases 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000013399 early diagnosis Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0600851 | 2006-01-31 | ||
| FR0600851A FR2896881B1 (fr) | 2006-01-31 | 2006-01-31 | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
| PCT/FR2007/050708 WO2007088305A1 (fr) | 2006-01-31 | 2007-01-30 | Procede de dosage du prongf pour le diagnostic in vitro du cancer en particulier du cancer du sein, de la thyroide ou du poumon et utilisation du prongf en therapie |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012124525A Division JP5792121B2 (ja) | 2006-01-31 | 2012-05-31 | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009525478A JP2009525478A (ja) | 2009-07-09 |
| JP2009525478A5 true JP2009525478A5 (enExample) | 2010-03-04 |
| JP5091876B2 JP5091876B2 (ja) | 2012-12-05 |
Family
ID=36741378
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552858A Active JP5091876B2 (ja) | 2006-01-31 | 2007-01-30 | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 |
| JP2012124525A Active JP5792121B2 (ja) | 2006-01-31 | 2012-05-31 | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012124525A Active JP5792121B2 (ja) | 2006-01-31 | 2012-05-31 | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8008009B2 (enExample) |
| EP (1) | EP1982192B1 (enExample) |
| JP (2) | JP5091876B2 (enExample) |
| CN (2) | CN101395478B (enExample) |
| ES (1) | ES2471126T3 (enExample) |
| FR (1) | FR2896881B1 (enExample) |
| WO (1) | WO2007088305A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2896881B1 (fr) * | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| EP2806054A1 (en) | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| FR2944019B1 (fr) * | 2009-04-03 | 2011-04-22 | Biomerieux Sa | Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal. |
| JP6078339B2 (ja) | 2009-05-07 | 2017-02-08 | ベラサイト インコーポレイテッド | 甲状腺状態の診断のための方法および組成物 |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| CN101782585A (zh) * | 2010-02-10 | 2010-07-21 | 广州医学院 | 肺癌组织蛋白印迹膜片及其制备方法 |
| WO2011159762A1 (en) * | 2010-06-15 | 2011-12-22 | Cornell University | Methods of limiting microvascular damage following acute myocardial ischemia |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| JP2014521958A (ja) * | 2011-07-28 | 2014-08-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法 |
| WO2013090620A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| ES2945036T3 (es) | 2012-08-16 | 2023-06-28 | Veracyte Sd Inc | Pronóstico del cáncer de próstata mediante biomarcadores |
| CN103122390B (zh) * | 2013-03-07 | 2015-04-08 | 上海市疾病预防控制中心 | Frat1基因作为检测甲状腺癌的血清标志物及其应用 |
| US10526655B2 (en) | 2013-03-14 | 2020-01-07 | Veracyte, Inc. | Methods for evaluating COPD status |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| CN103866039B (zh) * | 2014-04-04 | 2015-05-27 | 厦门大学 | 人类甲状腺癌组织基因特异位点甲基化水平检测引物及其应用 |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| EP2977759B1 (en) * | 2014-07-25 | 2017-07-12 | Serum Institute of India Private Limited | Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens |
| EP3770274A1 (en) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| LT3280441T (lt) | 2015-04-07 | 2021-11-25 | Alector Llc | Anti-sortilino antikūnai ir jų naudojimo būdai |
| US10849992B1 (en) | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
| US11414708B2 (en) | 2016-08-24 | 2022-08-16 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| AU2018210695B2 (en) | 2017-01-20 | 2024-07-18 | The University Of British Columbia | Molecular subtyping, prognosis, and treatment of bladder cancer |
| CA3051488A1 (en) * | 2017-01-24 | 2018-08-02 | Genetic Technologies Limited | Improved methods for assessing risk of developing breast cancer |
| US11873532B2 (en) | 2017-03-09 | 2024-01-16 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| WO2018205035A1 (en) | 2017-05-12 | 2018-11-15 | Genomedx Biosciences, Inc | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| EP3635399B1 (fr) * | 2017-06-08 | 2025-10-29 | Gnaho, Sylvain | Méthode d'isolement et de détection de cellules souches cancéreuses |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| WO2003076942A2 (fr) | 2002-03-13 | 2003-09-18 | Biomerieux | Quantification de cellules tumorales circulantes issues de cancers solides |
| FR2846426B1 (fr) * | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| ATE545429T1 (de) * | 2002-12-20 | 2012-03-15 | Lundbeck & Co As H | Modulation der neurotrophinaktivität;screeningsverfahren |
| WO2005076695A2 (en) * | 2004-02-11 | 2005-08-25 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| FR2896881B1 (fr) * | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
-
2006
- 2006-01-31 FR FR0600851A patent/FR2896881B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-30 ES ES07731536.4T patent/ES2471126T3/es active Active
- 2007-01-30 EP EP07731536.4A patent/EP1982192B1/fr active Active
- 2007-01-30 CN CN2007800040238A patent/CN101395478B/zh active Active
- 2007-01-30 JP JP2008552858A patent/JP5091876B2/ja active Active
- 2007-01-30 WO PCT/FR2007/050708 patent/WO2007088305A1/fr not_active Ceased
- 2007-01-30 CN CN2013103889291A patent/CN103446585A/zh active Pending
- 2007-01-30 US US12/087,606 patent/US8008009B2/en active Active
-
2011
- 2011-07-20 US US13/137,101 patent/US20110293636A1/en not_active Abandoned
-
2012
- 2012-05-31 JP JP2012124525A patent/JP5792121B2/ja active Active
- 2012-06-26 US US13/533,908 patent/US9061045B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525478A5 (enExample) | ||
| Houshmand et al. | Chronic myeloid leukemia stem cells | |
| Chen et al. | Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer | |
| Wilmott et al. | Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma | |
| Dine et al. | Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer | |
| Ugurel et al. | Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up | |
| Syn et al. | NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease | |
| Savas et al. | Clinical relevance of host immunity in breast cancer: from TILs to the clinic | |
| Wu et al. | Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo | |
| US9670550B2 (en) | Method for examination of carcinogenic risk | |
| US12352752B2 (en) | Application of Niemann-Pick C1 protein in diagnosis and treatment of cancer | |
| Saito et al. | Chaperone protein L-isoaspartate (D-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma | |
| Huang et al. | Cartilage decellularized matrix hydrogel loaded with protocatechualdehyde for targeted epiphycan treatment of osteoarthritis | |
| Wang et al. | The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography | |
| Dudek et al. | Antineoplastic effects of Rhodiola crenulata treatment on B16-F10 melanoma | |
| Tarhini et al. | Operable melanoma: screening, prognostication, and adjuvant and neoadjuvant therapy | |
| US20090226901A1 (en) | Method of evaluating or selecting agents for preventing or improving pigmented spots | |
| CN112262157A (zh) | 化药抗性癌症的组合治疗 | |
| Dai et al. | Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity | |
| Ollila-Raj et al. | Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing | |
| RU2436102C1 (ru) | Способ прогнозирования метастазов рака шейки матки | |
| CN102768281B (zh) | 用以评估肿瘤增生、侵犯或转移风险的生物标记及方法 | |
| WO2013029202A1 (zh) | 谷草转氨酶和乳酸脱氢酶的检测在早期评估抗肿瘤干预措施临床疗效中的应用 | |
| He et al. | The Expression of PD-L1, CD47, CD4, and CD8 in Breast Cancer before and after Neoadjuvant Chemotherapy and Their Relationship with Clinicopathological Features and Prognosis | |
| Lee et al. | A NON-GENETICALLY ENGINEERED EGFR SPECIFIC ARMED T-CELL THERAPY FOR TREATING EGFR-POSITIVE SOLID TUMORS |